News

In this newly formed position, Mr Russo will be responsible for overseeing sales and expanding the company’s market presence. Prior to joining InfuSystem, Mr Russo was regional vice

The first patient treated in the Dignity trial was at Rhode Island Hospital by principal investigator Brigid O’Connor. The other clinical sites participating in the trial include: the

Dr Smith has served as president of the Canadian Cardiovascular Society, chairman of the Scientific Review Committee of the Heart and Stroke Foundation of Canada, and president of

Pursuant to the terms of the agreement, the companies will jointly pursue world-wide business development opportunities with customers in the medical device market utilizing Covalon’s technologies. The companies

The program, active now at participating pharmacies, ensures patients with diabetes that their co-pay for Accu-Chek test strips will not exceed $25. The program provides a discount of

The study compared GI-5005 plus standard of care (SOC) – pegylated interferon and ribavirin – versus SOC alone in patients with chronic genotype 1 hepatitis C virus (HCV)

Aveo Pharmaceuticals has reported data from its preclinical models which demonstrates that the company’s potent and selective triple VEGF receptor inhibitor, AV-951, exhibits robust inhibitory activity in its

The Plus Phase IIa clinical trial was conducted in 32 chronic hepatitis C patients in the US who had failed prior treatment. The Plus trial was designed to

The trial will evaluate the dose and duration of treatment of R7128 in combination with Roche’s Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) – in hepatitis C virus (HCV)